NasdaqGS:AUTLBiotechs
A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data
Autolus Therapeutics (AUTL) just released its latest quarterly earnings and is drawing increased investor attention thanks to several key developments. The company continues to expand commercial access for Obe-cel, reports strong manufacturing results, and anticipates new data at the upcoming ASH conference.
See our latest analysis for Autolus Therapeutics.
Autolus Therapeutics has seen a burst of activity lately, from broadening commercial access and updating its leadership team to advancing...